- 1 Burden of diarrhea and antibiotic use among children in low-resource settings preventable by
- 2 *Shigella* vaccination: a simulation study
- 3
- 4 Stephanie A Brennhofer<sup>1</sup>, James A Platts-Mills<sup>1</sup>, Joseph A Lewnard<sup>2</sup>, Jie Liu<sup>3</sup>, Eric R Houpt<sup>1</sup>,
- 5 Elizabeth T Rogawski McQuade<sup>4\*</sup>
- 6
- <sup>1</sup>Division of Infectious Diseases & International Health, University of Virginia, Charlottesville,
   VA, USA
- 9
- <sup>2</sup>Division of Epidemiology, School of Public Health, University of California, Berkeley,
- 11 California, USA

USA

12

- <sup>13</sup> <sup>3</sup>School of Public Health, Qingdao University, Qingdao, Shandong, China
- <sup>4</sup>Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA,
- 16 17
- 18 \* Corresponding author:
- 19 E-mail: <u>erogaws@emory.edu</u>

#### 20 ABSTRACT

Background Shigella is a leading cause of diarrhea and dysentery in children in low resource 21 22 settings, which is frequently treated with antibiotics. The primary goal of a Shigella vaccine would be to reduce mortality and morbidity associated with Shigella diarrhea. However, 23 ancillary benefits could include reducing antibiotic use and antibiotic exposures for bystander 24 25 pathogens carried at the time of treatment, specifically for fluoroquinolones and macrolides (F/M), which are the recommended drug classes to treat dysentery. 26 27 Methods We used data from the Etiology, Risk Factors, and Interactions of Enteric Infections 28 and Malnutrition and the Consequences for Child Health and Development (MAL-ED) study to 29 estimate the impact of two one-dose (6 or 9 months) and three two-dose (6 & 9 months, 9 & 12 30 months, and 12 & 15 months) Shigella vaccines on diarrheal episodes, overall antibiotic use, and 31 32 F/M use. Further, we considered additional protection through indirect and boosting effects. To 33 estimate the absolute and relative reductions in the incidence of diarrhea and antibiotic use under each vaccination scenario, Monte Carlo simulations with random sampling were performed. 34 35 36 Findings We analyzed 9392 diarrhea episodes and 15697 antibiotic courses among 1715 children in the MAL-ED birth cohort study. There were 273.8 diarrhea episodes, 30.6 shigellosis 37 38 episodes, and 457.6 antibiotic courses per 100-child years. A Shigella vaccine given at 9 & 12 39 months prevented 1.7 (95% CI: 1.3, 2.1) severe Shigella diarrhea episodes (46.5% reduction), 40 11.0 (95% CI: 10.0, 11.9) Shigella diarrhea episodes of any severity (35.9% reduction), 3.1 (95% 41 CI: 2.6, 3.7) F/M courses (2.9% reduction overall), 5.8 (95% CI: 5.2, 6.6) antibiotic courses 42 (1.0% reduction overall), and 6.3 (95% CI: 5.2, 7.5) F/M (3.2% reduction) and 11.2 (95% CI:

43 9.7, 12.9) antibiotic (1.2% reduction) exposures to bystander pathogens, respectively, per 100-

44 child years.

45

- 46 Interpretation A Shigella vaccine could make substantial reductions in Shigella diarrhea,
- 47 antibiotic use to treat shigellosis, and bystander exposures due to shigellosis treatment. However,
- 48 the reductions in overall diarrhea episodes and antibiotic use would be modest.

49

50 **Funding** Wellcome Trust, Bill & Melinda Gates Foundation

#### 51 **INTRODUCTION**

Shigella is a leading cause of diarrhea and dysentery in children under the age of five in low- and 52 middle- income countries (LMICs)<sup>1</sup>. In the multisite Etiology, Risk Factors, and Interactions of 53 Enteric Infections and Malnutrition and the Consequences for Child Health and Development 54 (MAL-ED) cohort study, Shigella-attributed diarrhea was found to have an incidence of 26.1 55 episodes per 100 child years in the first two years of life.<sup>2</sup> There are several *Shigella* vaccines in 56 the pipeline, of which three are in phase IIA and one in phase III trials.<sup>3</sup> The World Health 57 Organization (WHO) recently published preferred product characteristics (PPC) for a Shigella 58 59 vaccine,<sup>1</sup> and efforts are underway to define the full value proposition for such a vaccine. The primary goal of a Shigella vaccine is to prevent mortality and moderate-to-severe episodes of 60 shigellosis with an efficacy target set by the WHO of 60% or more. Assuming this target can be 61 met in trials conducted in ideal settings, real world estimates of the reduction in diarrhea 62 episodes that would be expected after vaccine introduction are needed to predict population-level 63 vaccine impact. 64

65

Furthermore, a *Shigella* vaccine may produce ancillary benefits that need to be quantified,
specifically reductions in antibiotic exposures since diarrhea is a major cause of antibiotic use.<sup>4,5</sup>
Previous analyses have identified *Shigella* as a leading contributor to antibiotic consumption
among children in low-resource settings.<sup>5</sup> In MAL-ED, *Shigella* was responsible for 14.8
antibiotic courses per 100-child years.<sup>4</sup> Furthermore, 20.9% and 16.2% of all fluoroquinolone
and macrolide courses given for diarrhea, respectively, were to treat shigellosis.<sup>4</sup>

73	Vaccine impact on fluoroquinolone/macrolide (F/M) use is of particular interest as they are the
74	recommended treatment by the WHO for dysentery, <sup>6,7</sup> and 34% of dysentery cases in children
75	under two years of age in the MAL-ED birth cohort were attributed to Shigella. Frequent use of
76	antibiotics drives selection for drug resistant pathogens, <sup>8</sup> and drug-resistant shigellosis is of
77	concern. <sup>6</sup> Azithromycin and fluoroquinolone resistant strains of Shigella are common in Asia
78	and are growing in prevalence elsewhere. <sup>9–11</sup>
79	
80	In addition to preventing exposures to antibiotics for Shigella, a Shigella vaccine could further
81	reduce selective pressure on asymptomatic enteric pathogens (i.e., bystander pathogens) present
82	in the gut at the time of shigellosis treatment. Bystander pathogens are not the target of
83	treatment, but nonetheless are still exposed to antibiotics and are therefore at risk for
84	development of antimicrobial resistance (AMR). There were more than 7 antibiotic exposures
85	per child-year for bystander enteropathogenic bacteria in MAL-ED. <sup>5</sup>
86	
87	To inform the vaccine value proposition, we aimed to quantify the potential impact of a Shigella
88	vaccine on the incidence of Shigella diarrhea (severe and non-severe), all diarrhea, and antibiotic
89	use in the first two years of life via various potential vaccination strategies. We considered
90	different vaccine efficacies, dosing schedules, and types, including leaky vaccines (i.e.,
91	prevention of a fraction of episodes in all children) and all-or-nothing vaccines (i.e., prevention
92	of all episodes in a subset of children who are vaccine responders). <sup>12,13</sup> We also quantified the
93	potential impact of indirect protection to children who were too young to be vaccinated and the
94	impact of a vaccine that performs better for children who have been previously exposed to
95	Shigella.

96

#### 97 METHODS

#### 98 Study design and participants

99 The MAL-ED study design has been previously detailed.<sup>14</sup> Briefly, this study was conducted at

100 eight sites (Dhaka, Bangladesh; Fortaleza, Brazil; Vellore, India; Bhaktapur, Nepal; Loreto,

101 Peru; Naushero Feroze, Pakistan; Venda, South Africa; and Haydom, Tanzania) from November

102 2009 to February 2014. Children were enrolled within 17 days of birth and followed for two

103 years. Fieldworkers conducted twice weekly home visits to collect information on daily

104 antibiotic use and presence of illness. Stool samples were collected monthly (non-diarrheal

surveillance samples) and during diarrheal episodes. Diarrhea episodes were defined as three or

106 more loose stools in a 24-hour period or the presence of blood in at least one stool. Diarrhea

107 severity was determined by the modified Vesikari score, previously outlined.<sup>15</sup>

108

#### 109 Stool testing

110 The QIA amp Fast DNA Stool Mini Kit (Qiagen) was used to extract total nucleic acid from the

stool specimens.<sup>16</sup> To detect the presence of 29 enteropathogens via quantitative polymerase

112 chain reaction (qPCR), TaqMan Array Cards (TAC) were run using AgPath One Step RT PCR

113 kit (Thermo-Fisher).<sup>2</sup> The quantification cycle (Cq) to define pathogen detection was set to <35.

114 *Shigella spp.* were detected by the *ipaH* gene, as previously outlined.<sup>2</sup>

115

#### 116 Modeled vaccine impacts

117 We estimated the impact of vaccines on the following outcomes. First, *Shigella* diarrhea was

118 defined as diarrhea episodes with an episode-specific attributable fraction for *Shigella* (AFe)

119	>0.5, regardless of other pathogens detected. AFes were calculated as 1 - (1/ORe), where ORe
120	was the pathogen-specific and quantity-specific odds ratio (OR) from a generalized linear mixed
121	model associating pathogen quantity with diarrhea. <sup>2</sup> Second, severe Shigella diarrhea was
122	defined as <i>Shigella</i> diarrhea with a modified Vesikari score $>6$ . <sup>15</sup> Third, the number of severe
123	diarrhea episodes of any etiology was defined as diarrhea due to any cause with a modified
124	Vesikari score >6. Fourth, diarrhea episodes overall included any etiology and severity.
125	
126	For vaccine impacts on antibiotic use, we focused on F/Ms as specific drug classes of interest
127	and additionally assessed any antibiotic use. Each diarrhea episode was considered treated with
128	antibiotics if antibiotics were taken during any day of the illness episode. Antibiotic courses
129	overall were defined by antibiotic courses given to the child for any reason, as previously
130	determined. <sup>5</sup> Antibiotic courses were separated by two antibiotic-free days. Antibiotic exposures
131	to bystander pathogens (i.e., pathogens present at the time of antibiotic treatment, but that did not
132	cause the illness that was treated) were defined by linking each antibiotic course to the most
133	recent stool sample collected in the preceding 30 days. Any bacterial pathogens (atypical
134	enteropathogenic Escherichia coli (E.coli), Campylobacter, enteroaggregative E. coli,
135	enterotoxigenic E. coli, and typical enteropathogenic E. coli) detected in the linked stool were
136	assumed to be bystander pathogens during the antibiotic course. <sup>5</sup> Antibiotic exposures to
137	bystander pathogens were attributed to the treatment of Shigella if the antibiotic course was
138	given during a diarrhea episode with a <i>Shigella</i> AFe $> 0.5$ .
139	

140 Vaccination scenarios

141	The characteristics of our simulated Shigella vaccine were modeled after those outlined in the
142	WHO's PPC for a <i>Shigella</i> vaccine <sup>1</sup> and those from vaccines currently in the pipeline. We
143	considered one- and two- dose Shigella vaccines with multiple potential vaccine dosing
144	schedules: a one-dose vaccine with administration at 6 months or 9 months, and two dose
145	vaccines with administration at 6 & 9 months, 9 & 12 months, and 12 & 15 months (Table 1).
146	Vaccine efficacy 14 days after the second dose against severe Shigella diarrhea was simulated at
147	60% or 80% in separate scenarios. Efficacy against non-severe episodes was 40% and 60%,
148	respectively. Vaccine efficacy between the first dose up to 14 days after the second dose was half
149	that which was applied 14 days after the second dose. (Table 1).
150	
151	For scenarios that assumed the vaccine would produce indirect protection, we randomly selected
152	20% of Shigella diarrhea episodes that occurred in children under the age of the first dose of
153	vaccine administration to be prevented by the vaccine. These simulated levels of indirect
154	protection were based on what was observed with the Vi-tetanus toxoid conjugate vaccine in
155	Bangladesh. <sup>17</sup> For instance, under a scenario with vaccine doses administered at 9 & 12 months,
156	20% of diarrhea episodes occurring in children under the age of 9 months were randomly
157	prevented. For scenarios that assumed the vaccine would perform better among children
158	previously exposed to Shigella (i.e., boosting protection), efficacy was increased by an absolute
159	20% for Shigella diarrhea episodes that occurred in children who had a Shigella infection prior to
160	administration of the first dose of the vaccine. For example, in the 9- & 12-month dosing vaccine
161	scenario with 60% efficacy with 20% boosting effects, if a child was infected with Shigella prior
162	to 9 months of age, their allocated efficacy went from 60% to 80%.

164	Our primary simulated vaccine was a leaky vaccine, <sup>12,13</sup> for which we applied a constant
165	proportional reduction (equal to the efficacy) across all diarrhea episodes and antibiotic courses
166	(i.e., the vaccine prevented 60% of all diarrhea episodes or antibiotic courses). In a sensitivity
167	analysis, we simulated an all-or-nothing vaccine, <sup>12,13</sup> for which we selected a subset of children
168	who were vaccine responders at random, the size of which was defined by vaccine efficacy, and
169	prevented all diarrhea episodes and antibiotic courses in those children (i.e., all episodes among
170	60% of children were prevented).
171	
172	Results reported primarily in the text correspond to a leaky vaccine with two doses at 9 and 12
173	months with 60% efficacy since these characteristics may be the most realistic among the range

of acceptable parameters outlined in the WHO's PPC.<sup>1</sup> Results from all other vaccination

scenarios are described in the tables and figures.

176

#### 177 Statistical analysis

To estimate the incidence of each diarrhea and antibiotic outcome defined above expected under 178 each vaccination scenario, we performed Monte Carlo simulations using random sampling with 179 180 replacement of children to a sample size of 50,000. For each simulation, we randomly selected Shigella diarrhea episodes from these children to be prevented by a probability equal to vaccine 181 efficacy and calculated the incidence of each outcome excluding prevented episodes. In a no-182 183 vaccine scenario, no episodes were selected to be prevented. Estimates and confidence intervals were estimated by the median, 2.5<sup>th</sup> and 97.5<sup>th</sup> percentiles of 1,000 iterations of this procedure. 184 To quantify the expected reductions in the outcomes listed above, we estimated absolute and 185

relative differences and the percent change between each vaccine scenario and the no vaccinescenario.

188

All statistical analyses were performed via R software, version 4.0.2 (Foundation for Statistical

190 Computing).

191

#### 192 Ethics approvals and data availability

193 This study involves human participants. For the parent study, ethical approval was obtained from

194 the Institutional Review Boards at the University of Virginia School of Medicine

195 (Charlottesville, USA) (14595) and at each of the participating research sites: Ethical Review

196 Committee, ICDDR,B (Bangladesh); Committee for Ethics in Research, Universidade Federal do

197 Ceara; National Ethical Research Committee, Health Ministry, Council of National Health

198 (Brazil); Institutional Review Board, Christian Medical College, Vellore; Health Ministry

199 Screening Committee, Indian Council of Medical Research (India); Institutional Review Board,

200 Institute of Medicine, Tribhuvan University; Ethical Review Board, Nepal Health Research

201 Council; Institutional Review Board, Walter Reed Army Institute of Research (Nepal);

202 Institutional Review Board, Johns Hopkins University; PRISMA Ethics Committee; Health

203 Ministry, Loreto (Peru); Ethical Review Committee, Aga Khan University (Pakistan); Health,

204 Safety and Research Ethics Committee, University of Venda; Department of Health and Social

205 Development, Limpopo Provincial Government (South Africa); Medical Research Coordinating

206 Committee, National Institute for Medical Research; Chief Medical Officer, Ministry of Health

and Social Welfare (Tanzania). For the current study, we obtained ethical approval at the

208 University of Virginia School of Medicine (Charlottesville, USA) (22398) and Emory University

230	A leaky Shigella vaccine given at 9 & 12 months with 60% efficacy would be expected to
229	Prevention of diarrhea
228	
227	respectively.
226	per 100 child years resulting from any antibiotic use and resulting from the treatment of Shigella,
225	(n=427). Bystander pathogens had 646.1 (n=22161) and 32.9 (n=750) exposures to antibiotics
224	etiology and of which 16.3 courses per 100 child years were attributable to Shigella diarrhea
223	amongst which 110.1 courses per 100 child years (n=3775) were to treat diarrhea episodes of any
222	(n=754). Caregivers reported 457.6 courses per 100 child years of antibiotics (n=15697),
221	severity per 100 child-years (n=9392) and 30.6 Shigella diarrhea episodes per 100 child years
220	infection during their first two years of life (Table 2). There were 273.8 diarrhea episodes of any
219	These analyses included 1715 children, of which 83% (n=1427) had at least one Shigella
218	RESULTS
217	
216	publication.
215	interpretation of the data, writing of the report, nor in the decision to submit the paper for
214	The funders of this study did not have any role in the study design, collection, analysis,
213	Role of the funding source
212	
211	participant data from the MAL-ED study is publicly available at ClinEpiDB.org.
210	study before taking part. The statistical analysis plan is available at osf.io/3asxh. Deidentified
209	(Atlanta, USA) (STUDY00003285). Participants gave informed consent to participate in the

231 prevent 1.7 (95% CI: 1.3, 2.1) severe *Shigella* diarrhea episodes and 11.0 (95% CI: 10.0, 11.9)

232	Shigella diarrhea episodes of any severity per 100 child years (Table 3), which corresponds to a
233	46.5% reduction in severe shigellosis episodes and a 35.9% reduction in shigellosis episodes of
234	any severity (Figure 1, Supp Table 1). While the vaccine would reduce the same number of
235	severe and all diarrhea episodes due to any etiology, the percent reductions would be smaller, at
236	3.7% for severe diarrhea episodes of any etiology and 4.0% for diarrhea episodes of any etiology
237	(Table 3, Figure 1, Supp Table 1).
238	
239	The 11.0 (95% CI: 10.0, 11.9) prevented Shigella diarrhea episodes per 100 child years increased
240	slightly to 11.5 (95% CI: 10.6, 12.5) when analyses further allowed for 20% indirect protection
241	(Supp Table 2). This same vaccine with 20% boosting protection and no indirect protection
242	would prevent 12.8 (95% CI: 11.7, 14.0) Shigella diarrhea episodes (Supp Table 3). Together, a
243	vaccine with direct effects plus indirect and boosting protection effects would prevent 13.4 (95%
244	CI: 12.3, 14.5) Shigella diarrhea episodes per 100 child years (Supp Table 4), which equates to a
245	43.7% reduction in Shigella diarrhea episodes and a 54.5% reduction in severe Shigella diarrhea
246	episodes (Figure 2, Supp Table 5).

247

#### 248 **Prevention of antibiotic use**

A two-dose *Shigella* vaccine given at 9 and 12 months with 60% vaccine efficacy could prevent 0.5 (95% CI: 0.2, 0.7) F/M treated severe *Shigella* diarrhea episodes (48.4% reduction), 3.1 (95% CI: 2.6, 3.7) F/M treated *Shigella* episodes (37.3% reduction), and 6.3 (95% CI: 5.2, 7.5) F/M exposures to bystander pathogens due to *Shigella* treatment (36.2% reduction) per 100 child years (Table 4, Figure 3, Supp Table 6). However, this vaccine would reduce overall F/M uses and overall F/M exposures to bystander pathogens by only 2.9% and 3.2%, respectively (Supp

Table 6). The 3.1 (95% CI: 2.6, 3.7) prevented F/M treated Shigella diarrhea episodes per 100 255 child years increased to 3.2 (95% CI: 2.7, 3.7) prevented episodes with added indirect protection 256 257 effects (Supp Table 7), to 3.6 (95% CI: 3.0, 4.3) with added boosting effects (Supp Table 8), and to 3.7 (95% CI: 3.1, 4.4) when both indirect effects and boosting effects were added to the direct 258 effects (Supp Table 9). When indirect and boosting effects were added to the direct effects, there 259 260 were slight increases in percent reductions of all metrics: F/M treated Shigella diarrhea episodes 261 (37.3% to 45.1%), F/M courses overall (2.9% to 3.5%), F/M exposures to bystander pathogens 262 due to *Shigella* treatment (36.2% to 44.6%), and F/M exposures to bystander pathogens overall 263 (3.2% to 3.9%) (Figure 4, Supp Table 10).

264

While a two-dose *Shigella* vaccine given at 9 and 12 months with 60% vaccine efficacy would 265 266 prevent more instances of antibiotic use overall than of F/M specifically, the percent reductions in overall antibiotic use were smaller than what was observed with F/M use (Supp Table 11, 267 268 Supp Figure 1, Supp Table 12). In this scenario, 1.1 (95% CI: 0.7, 1.4) courses of antibiotic treated severe Shigella diarrhea episodes (41.3% reduction), 5.8 (95% CI: 5.2, 6.6) antibiotic 269 treated Shigella diarrhea episodes (35.6% reduction), and 11.2 (95% CI: 9.7, 12.9) antibiotic 270 271 exposures to bystander pathogens due to *Shigella* treatment (35.0% reduction) per 100 child years were prevented (Supp Table 11, Supp Figure 2, Supp Table 12). However, there was only a 272 273 1.0% and 1.2% reduction in overall antibiotic uses and overall exposures to bystander pathogens, 274 respectively (Supp Table 12). Similar to what was observed with F/M, the addition of indirect 275 and boosting effects onto the direct effects minimally increased the number of prevented 276 outcomes (Supp Table 13-16, Supp Figure 2).

#### 278 All-or-nothing vaccine compared to leaky vaccine

279	A Shigella vaccine given at 9 & 12 months that fully protected 60% of children (i.e., an all-or-
280	nothing vaccine) prevented the same number of severe Shigella diarrhea episodes (1.7 (95% CI:
281	1.3, 2.1) episodes per 100 child years) as the leaky vaccine (i.e., prevented 60% of episodes
282	across children) (Table 3, Supp Table 17). However, the all-or-nothing vaccine prevented more
283	Shigella diarrhea episodes of any severity compared to the leaky vaccine (15.6 (95% CI: 14.3,
284	17.0) vs. 11.0 (95% CI: 10.0, 11.9) episodes per 100 child years) (Table 3, Supp Table 17).
285	Similar results were found for the antibiotic outcomes, such that an all-or-nothing vaccine would
286	be expected to prevent more of all outcomes except the severe outcomes, for which it would
287	prevent the same number as a leaky vaccine (Supp Table 18, Supp Table 19).
288	
289	The corresponding results for the other vaccine scenarios listed in Table 1 are displayed in
290	Figures 1-2, Tables 3-4, Supp Figure 2, Supp Tables 1-4, 6-9, 11-15, 17-19). In general, the
291	earlier the vaccine is given, the greater the expected reduction in diarrhea episodes and antibiotic
292	use. Additionally, the single dose vaccines were more efficacious than the two-dose vaccines
293	initiated at the same time (e.g., one-dose at 9 months vs. two-doses at 9 and 12 months) since the
294	full efficacy was achieved at an earlier age with the single dose vaccines.
295	
296	DISCUSSION

A leaky *Shigella* vaccine administered at 9 and 12 months with 60% vaccine efficacy could
provide a substantial reduction in severe *Shigella* diarrhea episodes, *Shigella* diarrhea episodes of
any severity, and F/M treated *Shigella* diarrhea episodes. However, given the multitude of causes
of diarrhea and antibiotic use in this population, the expected reductions in all-cause diarrhea and

antibiotic use overall were modest (<5%). While single-dose vaccines and vaccines given at</li>
younger ages would prevent more diarrhea and antibiotic use, none of the vaccine candidates in
clinical development meet those criteria.

304

Incorporation of indirect protection and boosting only slightly increased the number of diarrhea 305 306 episodes and antibiotic courses expected to be preventable, suggesting these nuances will not be major determinants of vaccine success. A Shigella vaccine will likely fall somewhere on the 307 308 continuum between a leaky (i.e., prevention of a fraction of episodes in all children) and all-or-309 nothing (i.e., prevention of all episodes in a subset of children who are vaccine responders) vaccine.<sup>12,13</sup> As expected, the all-or-nothing vaccine effects were larger than the leaky vaccine 310 effects for outcomes that were not limited to severe diarrhea because an all-or-nothing vaccine 311 would provide complete protection in a subset of individuals regardless of disease severity. 312 However, our analysis was limited by assuming that vaccine responders were a random subset of 313 314 the population. It may be more likely that vaccine responders would be expected to be at lower risk of shigellosis even in the absence of vaccine. Furthermore, while our results estimate the 315 upper limit of the potential benefit of a *Shigella* vaccine since we assumed 100% vaccine 316 317 coverage, it is likely that vaccine coverage would be lower in a real-world setting.

318

The absolute reductions in F/M use achieved by a *Shigella* vaccine accounted for roughly half the achievable reduction of all antibiotic use. However, there were greater percent reductions in F/M use compared to all antibiotic use since F/Ms are often targeted for diarrhea treatment, and specifically for dysentery presumed to be shigellosis. F/M use has been associated with resistance in these drug classes,<sup>5,8,18</sup> suggesting reductions in use achievable by a *Shigella* 

324	vaccine could limit drug-resistant shigellosis as well as the development of resistance in other
325	enteric bacteria through reductions in bystander exposure. Our predicted reductions in all
326	antibiotic and F/M use could be underestimates if suspicion of Shigella is the main reason for
327	treating diarrhea regardless of etiology, such that treatment rates also decline for other diarrhea
328	etiologies after Shigella incidence is known to have been substantially reduced by the vaccine.
329	As Shigella vaccines are evaluated in large Phase III trials, data on antibiotic treatment should be
330	carefully collected such that the impact of the vaccine on antibiotic use can be measured. <sup>1,19</sup> To
331	quantify this impact, it will be important for vaccine effectiveness to be estimated against less-
332	severe disease endpoints which account for the bulk of antibiotic use.
333	
334	The vaccine scenarios modeled are in line with the WHO PPC guidance. However, some of the
335	current vaccines in the pipeline require more doses. There is one phase III Shigella vaccine
336	(ZF0901 (Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd.)) <sup>20</sup> and three phase IIA Shigella
337	vaccines (Shigella4V (Limmatech AG) <sup>21</sup> , altSonflex1-2-3 (GVGH), <sup>22</sup> and GlycoShig3 (Institut
338	Pasteur) <sup>23</sup> ) in the pipeline. <sup>3</sup> ZF0901 is 3 doses for infants ages 3-6 months and 2 doses for those
339	aged 6-12 months. Shigella4V is 3 doses for infants (8 months +/- 1 month) and children (2-5
340	years). altSonflex1-2-3 is 3 doses for infants 9 months of age and changes to 2 doses for children
341	24-59 months. GlycoShig3 is 3 doses infants (9 months +/- 1 month) and children (2-5 years).
342	For our age group of interest (children under two years of age), the aforementioned vaccines
343	would all require 2-3 doses. Our estimates of the expected reductions in outcomes would apply
344	to a three-dose vaccine where the full efficacy is achieved after two doses. If full efficacy is not
345	achieved until a third dose, our expected reductions may be overestimated.

347

348	A Shigella vaccine will likely not be protective against all serotypes, but given the lack of
349	serotyping data, we were unable to simulate the prevention of episodes at the serotype level.
350	However, there is no need for a <i>Shigella</i> vaccine to contain all 49 serotypes for broad coverage.
351	Shigella flexneri (S. flexneri) is the leading cause of endemic diarrhea in LMICs while Shigella
352	sonnei (S. sonnei) is the leading cause in high income countries. <sup>6</sup> While there are 15 serotypes
353	for S. flexneri, five (2a, 1b, 2b, 3a, 6) accounted for 89% of S. flexneri isolates from the Global
354	Enteric Multicenter Study (GEMS). <sup>24</sup> On a yearly basis, there are minimal changes to the
355	dominant Shigella serotypes. Therefore, a quadrivalent vaccine with S. sonnei and S. flexneri 2a,
356	3a, and 6 could provide 64% protection against Shigella with coverage up to 88% via cross
357	protection. <sup>24</sup> Our estimates assume 100% cross protection for subtypes not included in the
358	vaccine and therefore may be slightly overestimated depending on the true levels of cross
359	protection observed.

360

Finally, we did not consider the potential for waning immunity since we only observed outcomes to two years of age. The effects of waning would likely occur more than 6 months after the last vaccine dose, which was outside of our follow-up period for most vaccine scenarios. However, if efficacy wanes substantially before two years of age, our expected reductions may also be overestimated. Since waning may vary by endpoint (i.e., more pronounced waning for less severe disease), this will be another important feature to monitor in trials.

367

It is important to note that while we targeted efficacies at 60% and 80%, those proportions ofoutcomes were not prevented at the population level for two reasons: 1) targeted efficacies of

370 60% and 80% were for severe diarrhea only (as per the PPC) whereas efficacy was lower for non-severe diarrhea and 2) episodes that occur prior to vaccination would not be expected to be 371 prevented. Because severe disease is more common in younger children, the expected relative 372 reductions in severe outcomes were particularly less for vaccine strategies with older ages of 373 administration. However, given the high burden of shigellosis and antibiotic treatment of 374 375 shigellosis, a Shigella vaccine could still make a substantial impact on Shigella diarrhea burden in term of absolute reduction in episodes, and have ancillary benefits in the reduction of 376 377 antibiotic use.

378

Our estimates provide more realistic expectations for the reductions in diarrhea outcomes at the 379 380 population-level that could be achieved by *Shigella* vaccines under real world introduction 381 scenarios. A previous modeling study estimated similar absolute reductions in *Shigella* diarrhea episodes under a more limited set of vaccine assumptions that did not account for partial 382 protection after a first dose, herd immunity, or effects on antibiotic use.<sup>25</sup> Uniquely, we 383 demonstrate that Shigella vaccines could provide important reductions in antibiotic use for 384 severe and non-severe *Shigella* diarrheal episodes, and exposures to bystander pathogens due to 385 386 Shigella treatment. Given the high burden of enteric infections and antibiotic use among children in LMICs, the value proposition of a *Shigella* vaccine in this population is strong and 387 388 substantially augmented by the projected impacts on antibiotic use.

#### 389 ACKNOWLEDGEMENT

- 390 This work was supported by Wellcome (219741/Z/19/Z to ETRM). The Etiology, Risk Factors
- and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health
- and Development Project (MAL-ED) was a collaborative project supported by the Bill &
- 393 Melinda Gates Foundation (OPP1131125), the Foundation for the NIH, the National Institutes of
- Health, and the Fogarty International Center.

395

#### 396 DATA SHARING

- 397 De-identified participant data from the MAL-ED study is publicly available at ClinEpiDB.org
- after approval of a proposal by the study PIs.

399

#### 400 AUTHORS' CONTIBUTIONS

- 401 SAB and ETRM led data analysis, visualization, interpretation, and writing of the report. JAP-M
- 402 contributed to data analysis, methodology, and visualization. JAP-M and JAL contributed to
- 403 interpretation. JL led the development of the laboratory assays. ERH led funding acquisition and
- 404 administration of the parent study. JAP-M, JAL, JL, and ERH contributed to reviewing/editing
- 405 the report. ETRM led conceptualization, methodology, and funding acquisition.

406

#### 407 DECLARATION OF INTEREST

408 We declare no competing interests.

#### 409 **REFERENCES**

- 410
- 411 1. WHO preferred product characteristics for vaccines against Shigella. Accessed January 19,
   412 2023. https://www.who.int/publications-detail-redirect/9789240036741
- 2. Platts-Mills JA, Liu J, Rogawski ET, et al. Use of quantitative molecular diagnostic methods
  to assess the aetiology, burden, and clinical characteristics of diarrhoea in children in lowresource settings: a reanalysis of the MAL-ED cohort study. *The Lancet Global Health*.
- 416 2018;6(12):e1309-e1318. doi:10.1016/S2214-109X(18)30349-8
- 417 3. Immunization, Vaccines and Biologicals. Published April 30, 2022. Accessed January 19,
   418 2023. https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/shigella
- 4. Brennhofer SA, Platts-Mills JA, Lewnard JA, Liu J, Houpt ER, Rogawski McQuade ET.
  Antibiotic use attributable to specific aetiologies of diarrhoea in children under 2 years of age
  in low-resource settings: a secondary analysis of the MAL-ED birth cohort. *BMJ Open*.
  2022:12(4):058740, doi:10.1136/bmiopen.2021.058740.
- 422 2022;12(4):e058740. doi:10.1136/bmjopen-2021-058740
- 5. Rogawski McQuade ET, Brennhofer SA, Elwood SE, et al. Frequency of bystander exposure to antibiotics for enteropathogenic bacteria among young children in low-resource settings. *Proceedings of the National Academy of Sciences*. 2022;119(36):e2208972119.
  doi:10.1073/pnas.2208972119
- 427 6. Kotloff KL, Riddle MS, Platts-Mills JA, Pavlinac P, Zaidi AKM. Shigellosis. *The Lancet*.
  428 2018;391(10122):801-812. doi:10.1016/S0140-6736(17)33296-8
- 429 7. World Health Organization. *Guidelines for the control of shigellosis, including epidemics due*430 *to Shigella dysenteriae type 1.* World Health Organization; 2005. Accessed January 20, 2023.
  431 https://apps.who.int/iris/handle/10665/43252
- 8. Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and metaanalysis of the effects of antibiotic consumption on antibiotic resistance. *BMC Infectious Diseases*. 2014;14(1):13. doi:10.1186/1471-2334-14-13
- 435 9. Kasumba IN, Badji H, Powell H, et al. Shigella in Africa: New Insights From the Vaccine
  436 Impact on Diarrhea in Africa (VIDA) Study. *Clinical Infectious Diseases*.
  437 2023;76(Supplement\_1):S66-S76. doi:10.1093/cid/ciac969
- 438 10. Chung The H, Baker S. Out of Asia: the independent rise and global spread of
  439 fluoroquinolone-resistant Shigella. *Microb Genom.* 2018;4(4):e000171.
  440 doi:10.1099/mgen.0.000171
- Salleh MZ, Nik Zuraina NMN, Hajissa K, Ilias MI, Banga Singh KK, Deris ZZ.
   Prevalence of Multidrug-Resistant and Extended-Spectrum Beta-Lactamase-Producing
- 443 Shigella Species in Asia: A Systematic Review and Meta-Analysis. *Antibiotics*.
- 444 2022;11(11):1653. doi:10.3390/antibiotics11111653

Halloran ME, Haber M, Longini IM. Interpretation and estimation of vaccine efficacy
under heterogeneity. *Am J Epidemiol*. 1992;136(3):328-343.

doi:10.1093/oxfordjournals.aje.a116498

# MAGPANTAY FMG, RIOLO MA, DE CELLÈS MD, KING AA, ROHANI P. EPIDEMIOLOGICAL CONSEQUENCES OF IMPERFECT VACCINES FOR IMMUNIZING INFECTIONS. *SIAM J Appl Math.* 2014;74(6):1810-1830.

- 451 doi:10.1137/140956695
- 14. The MAL-ED Network Investigators. The MAL-ED Study: A Multinational and
  Multidisciplinary Approach to Understand the Relationship Between Enteric Pathogens,
  Malnutrition, Gut Physiology, Physical Growth, Cognitive Development, and Immune
  Responses in Infants and Children Up to 2 Years of Age in Resource-Poor Environments. *Clinical Infectious Diseases*. 2014;59(suppl\_4):S193-S206. doi:10.1093/cid/ciu653
- Platts-Mills JA, Babji S, Bodhidatta L, et al. Pathogen-specific burdens of community
  diarrhoea in developing countries: a multisite birth cohort study (MAL-ED). *The Lancet Global Health*. 2015;3(9):e564-e575.
- Liu J, Kabir F, Manneh J, et al. Development and assessment of molecular diagnostic
  tests for 15 enteropathogens causing childhood diarrhoea: a multicentre study. *The Lancet Infectious Diseases*. 2014;14(8):716-724. doi:10.1016/S1473-3099(14)70808-4
- 463 17. Qadri F, Khanam F, Liu X, et al. Protection by vaccination of children against typhoid
  464 fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised
  465 trial. *The Lancet*. 2021;398(10301):675-684. doi:10.1016/S0140-6736(21)01124-7
- Bergman M, Huikko S, Huovinen P, Paakkari P, Seppälä H, Finnish Study Group for
  Antimicrobial Resistance (FiRe Network). Macrolide and azithromycin use are linked to
  increased macrolide resistance in Streptococcus pneumoniae. *Antimicrob Agents Chemother*.
  2006;50(11):3646-3650. doi:10.1128/AAC.00234-06
- Vekemans J, Hasso-Agopsowicz M, Kang G, et al. Leveraging Vaccines to Reduce
  Antibiotic Use and Prevent Antimicrobial Resistance: A World Health Organization Action
  Framework. *Clin Infect Dis.* 2021;73(4):e1011-e1017. doi:10.1093/cid/ciab062
- 473 20. Mo Y, Fang W, Li H, et al. Safety and Immunogenicity of a Shigella Bivalent Conjugate
  474 Vaccine (ZF0901) in 3-Month- to 5-Year-Old Children in China. *Vaccines (Basel)*.
  475 2021;10(1):33. doi:10.3390/vaccines10010033
- LimmaTech Biologics AG. Safety and Immunogenicity of a Shigella-Tetravalent *Bioconjugate Vaccine: A Phase 1/2 Randomized Controlled and Age Descending Study Including Dose Finding in 9 Month Old Infants.* clinicaltrials.gov; 2022. Accessed April 23,
  2023. https://clinicaltrials.gov/ct2/show/NCT04056117
- 480 22. GlaxoSmithKline. A Staged Phase I/II Observer-Blind, Randomised, Controlled, Multi481 Country Study to Evaluate the Safety, Reactogenicity, and Immune Responses to the GVGH
  482 AltSonflex1-2-3 Vaccine Against S. Sonnei and S. Flexneri, Serotypes 1b, 2a, and 3a, in Adults

- 483 *in Europe (Stage 1) Followed by Age De-Escalation From Adults to Children and Infants, and*
- 484 Dose-Finding in Infants in Africa (Stage 2). clinicaltrials.gov; 2022. Accessed January 19,
- 485 2023. https://clinicaltrials.gov/ct2/show/NCT05073003
- 486 23. Institut Pasteur. A Phase 2a Age Descending Study to Investigate the Safety and
   487 Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-Based Conjugate Vaccine Against
- 488 Shigella Flexneri 2a in Adults, Children, and Infant Target Population in Endemic Countries.
- 489 clinicaltrials.gov; 2023. Accessed January 19, 2023.
- 490 https://clinicaltrials.gov/ct2/show/NCT04602975
- 491 24. Livio S, Strockbine NA, Panchalingam S, et al. Shigella Isolates From the Global Enteric
  492 Multicenter Study Inform Vaccine Development. *Clinical Infectious Diseases*.
- 493 2014;59(7):933-941. doi:10.1093/cid/ciu468
- 494 25. Anderson JD, Bagamian KH, Pecenka CJ, et al. Potential impact and cost-effectiveness
- 495 of Shigella vaccination in 102 low-income and middle-income countries in children aged 5
- 496 years or younger: a modelling study. *The Lancet Global Health*. 2023;11(6):e880-e891.
- 497 doi:10.1016/S2214-109X(23)00192-4

mun cet a	ind boosting protect	1011.					
Scenario	Dosing schedule	<i>Shigella</i> diarrhea Severity	Efficacy 14 days after 1 <sup>st</sup> dose	Efficacy 14 days after 2 <sup>nd</sup> dose	Indirect effect	Boosting effect after 1 <sup>st</sup> dose, before 2 <sup>nd</sup> dose	Boosting effect after 2 <sup>nd</sup> dose
0	No vaccine						
1	1 <sup>st</sup> : 6 months	Severe	60%		20%	+20% (80% VE)	
2	1 <sup>st</sup> : 9 months	Severe	40% 60%		20% 20%	+20% (80% VE) +20% (80% VE)	
2	1 <sup>st</sup> : 6 months	Non-severe Severe	40% 30%	 60%	20% 20%	+20% (60% VE) +10% (40% VE)	 +20% (80% VE)
3	2 <sup>nd</sup> : 9 months	Non-severe	20%	40%	20%	+10% (30% VE)	+20% (60% VE)
4	$1^{\text{st}}$ : 9 months $2^{\text{nd}}$ : 12 months	Severe	30%	60%	20%	+10% (40% VE)	+20% (80% VE)
		Non-severe	20%	40%	20%	+10% (30% VE)	+20% (60% VE)
5	$2^{nd}$ : 15 months	Severe	30%	60%	20%	+10% (40% VE)	+20% (80% VE)
		Non-severe	20%	40%	20%	+10% (30% VE)	+20% (60% VE)
6	1 <sup>st</sup> : 6 months	Severe	80%		20%	+20% (100% VE)	
7	1 <sup>st</sup> : 9 months	Non-severe Severe	60% 80%		20% 20%	+20% (80% VE) +20% (100% VE)	
/	1 st c 1	Non-severe	60%		20%	20% (80% VE)	
8	$2^{nd}$ : 9 months	Severe	40%	80%	20%	+10% (50% VE)	+20% (100% VE)
	1st O d	Non-severe	30%	60%	20%	+10% (40% VE)	+20% (80% VE)
9	$2^{nd}$ : 12 months	Severe	40%	80%	20%	+10% (50% VE)	+20% (100% VE)
	1 st. 10	Non-severe	30%	60%	20%	+10% (40% VE)	+20% (80% VE)
10	$1^{\text{ac}}$ : 12 months $2^{\text{nd}}$ : 15 months	Severe	40%	80%	20%	+10% (50% VE)	+20% (100% VE)
		Non-severe	30%	60%	20%	+10% (40% VE)	+20% (80% VE)

Table 1. *Shigella* vaccination scenarios simulated in the MAL-ED dataset, including dosing schedules, efficacies, and inclusion of indirect and boosting protection.

Table 2. Diarrhea epis	sodes, antibiotic use	, and bystander patho	ogen exposures to antibiotics amon	ng 1715 children enrolled in the MAL-ED cohor
1	/			8

	<6 months	$\geq$ 6 months,	$\geq 9$ months, $< 12$	$\geq$ 12 months,	$\geq$ 15 months	
		<9 months	months	<15 months		
No. children with their first instance of a Shigella infection, n (%) <sup>a,d</sup>	163 (9.5)	199 (11.6)	275 (16.0)	251 (14.6)	539 (31.4)	
No. severe <i>Shigella</i> diarrhea episodes, n (rate) <sup>b,c,d</sup>	5 (0.8)	9 (2.9)	10 (3.2)	17 (5.5)	48 (5.2)	
No. severe diarrhea episodes of any etiology, n (rate) <sup>b,c,</sup>	434 (50.6)	286 (66.7)	192 (44.8)	186 (43.4)	290 (22.5)	
No. <i>Shigella</i> diarrhea episodes, n (rate) <sup>b,c,d</sup>	16 (2.6)	43 (14.0)	84 (27.3)	118 (38.3)	493 (53.3)	
No. diarrhea episodes of any etiology, n (rate) <sup>b,c,</sup>	2386 (278.3)	1498 (349.4)	1333 (310.9)	1236 (288.3)	2939 (228.5)	
No. antibiotic treated severe Shigella diarrhea episodes, n (rate) <sup>b,d</sup>	6 (0.9)	6 (1.7)	12 (3.5)	12 (3.5)	32 (3.1)	
No. antibiotic treated severe diarrhea episodes of any etiology, n (rate) <sup>b</sup>	253 (29.5)	206 (48)	145 (33.8)	103 (24.0)	184 (14.3)	
No. antibiotic treated <i>Shigella</i> diarrhea episodes, n (rate) <sup>b,d</sup>	11 (1.6)	24 (6.9)	53 (15.2)	73 (21.0)	266 (25.5)	
No. antibiotic treated diarrhea episodes of any etiology, n (rate) <sup>b</sup>	804 (93.8)	629 (146.7)	588 (137.1)	480 (112.0)	1274 (99.0)	
No. antibiotic courses overall, n (rate) <sup>b</sup>	3478 (405.6)	2283 (532.5)	2164 (504.7)	2105 (491.0)	5667 (440.6)	
No. antibiotic exposures to bystander pathogens due to <i>Shigella</i> treatment, n (rate) <sup>b,d</sup>	25 (3.6)	39 (11.2)	102 (29.3)	133 (38.3)	451 (43.2)	
No. antibiotic exposures to bystander pathogens overall, n (rate) <sup>b</sup>	2736 (319.1)	3404 (793.9)	3641 (849.2)	3527 (822.6)	8853 (688.3)	
<sup>a</sup> denominator = 1715 kids; <sup>b</sup> Rate is per 100 child years; <sup>c</sup> Includes episodes that were and were not treated by antibiotics; <sup>d</sup> Counted among infections/episodes/exposures in which stools						
were collected with valid qPCR test results for Shigella; rates are extrapolated to all infections/episodes/exposures						

	Absolute	difference	Relative difference		
Vaccine scenario and efficacy outcome	(cases per 10	0 child-years)			
	60% VE	80% VE	60% VE	80% VE	
	(95% CI)	(95% CI)	(95% CI)	(95% CI)	
One dose - 6 months					
Severe Shigella diarrhea episodes	2.0 (1.6, 2.5)	2.7 (2.2, 3.4)	0.43 (0.40, 0.47)	0.24 (0.21, 0.29)	
Severe diarrhea episodes of any etiology	2.0 (1.6, 2.5)	2.7 (2.2, 3.4)	0.96 (0.95, 0.96)	0.94 (0.93, 0.95)	
Shigella diarrhea episodes	12.6 (11.6, 13.7)	18.6 (17.1, 20.2)	0.59 (0.58, 0.60)	0.39 (0.38, 0.40)	
Diarrhea episodes of any etiology	12.6 (11.6, 13.7)	18.6 (17.1, 20.2)	0.95 (0.95, 0.96)	0.93 (0.93, 0.94)	
One dose - 9 months					
Severe Shigella diarrhea episodes	1.8 (1.4, 2.3)	2.4 (1.8, 3.0)	0.50 (0.45, 0.55)	0.33 (0.27, 0.40)	
Severe diarrhea episodes of any etiology	1.8 (1.4, 2.3)	2.4 (1.8, 3.0)	0.96 (0.95, 0.97)	0.95 (0.94, 0.96)	
Shigella diarrhea episodes	11.8 (10.8, 12.7)	17.3 (15.9, 18.8)	0.62 (0.60, 0.63)	0.43 (0.42, 0.45)	
Diarrhea episodes of any etiology	11.8 (10.8, 12.7)	17.3 (15.9, 18.8)	0.96 (0.95, 0.96)	0.94 (0.93, 0.94)	
Two doses - 6 months & 9 months					
Severe Shigella diarrhea episodes	1.9 (1.5, 2.4)	2.6 (2.0, 3.2)	0.47 (0.43, 0.51)	0.29 (0.24, 0.34)	
Severe diarrhea episodes of any etiology	1.9 (1.5, 2.4)	2.6 (2.0, 3.2)	0.96 (0.95, 0.97)	0.94 (0.93, 0.96)	
Shigella diarrhea episodes	12.2 (11.2, 13.2)	17.9 (16.5, 19.4)	0.60 (0.59, 0.61)	0.41 (0.40, 0.43)	
Diarrhea episodes of any etiology	12.2 (11.2, 13.2)	17.9 (16.5, 19.4)	0.96 (0.95, 0.96)	0.93 (0.93, 0.94)	
Two doses - 9 months & 12 months					
Severe Shigella diarrhea episodes	1.7 (1.3, 2.1)	2.2 (1.7, 2.8)	0.53 (0.49, 0.59)	0.38 (0.32, 0.45)	
Severe diarrhea episodes of any etiology	1.7 (1.3, 2.1)	2.2 (1.7, 2.8)	0.96 (0.95, 0.97)	0.95 (0.94, 0.96)	
Shigella diarrhea episodes	11.0 (10.0, 11.9)	16.2 (14.8, 17.6)	0.64 (0.63, 0.65)	0.47 (0.45, 0.49)	
Diarrhea episodes of any etiology	11.0 (10.0, 11.9)	16.2 (14.8, 17.6)	0.96 (0.96, 0.96)	0.94 (0.94, 0.95)	
Two doses - 12 months & 15 months					
Severe Shigella diarrhea episodes	1.4 (1.0, 1.7)	1.8 (1.4, 2.3)	0.62 (0.56, 0.67)	0.49 (0.42, 0.57)	
Severe diarrhea episodes of any etiology	1.4 (1.0, 1.7)	1.8 (1.4, 2.3)	0.97 (0.96, 0.98)	0.96 (0.95, 0.97)	
Shigella diarrhea episodes	9.1 (8.3, 10.0)	13.4 (12.2, 14.7)	0.70 (0.69, 0.72)	0.56 (0.54, 0.58)	
Diarrhea episodes of any etiology	9.1 (8.3, 10.0)	13.4 (12.2, 14.7)	0.97 (0.96, 0.97)	0.95 (0.95, 0.96)	

Table 3. Absolute and relative differences in diarrhea outcomes among five vaccine scenarios with 60% and 80% full vaccine efficacies and no indirect or boosting protection.

Vaccine scenario and efficacy outcome	Absolute	difference	Relative difference	
	(cases per 10	0 child-years)		
·	60% VE (95% CI)	80% VE (95% CI)	60% VE (95% CI)	80% VE (95% CI)
One dose - 6 months				
F/M treated severe Shigella diarrhea episodes	0.5 (0.3, 0.8)	0.7 (0.4, 1.0)	0.45 (0.38, 0.56)	0.27 (0.19, 0.41)
F/M treated severe diarrhea episodes of any etiology	0.5 (0.3, 0.8)	0.7 (0.4, 1.0)	0.92 (0.89, 0.95)	0.90 (0.85, 0.94)
F/M treated Shigella diarrhea episodes	3.4 (2.9, 4.0)	5.1 (4.3, 5.9)	0.58 (0.57, 0.60)	0.39 (0.37, 0.41)
F/M treated diarrhea episodes of any etiology	3.4 (2.9, 4.0)	5.1 (4.3, 5.9)	0.91 (0.90, 0.92)	0.87 (0.85, 0.88)
F/M courses overall	3.4 (2.9, 4.0)	5.1 (4.3, 5.9)	0.97 (0.96, 0.97)	0.95 (0.95, 0.96)
F/M exposures to bystander pathogens due to Shigella treatment	7.2 (5.9, 8.4)	10.6 (8.8, 12.5)	0.59 (0.57, 0.61)	0.39 (0.37, 0.42)
F/M exposures to bystander pathogens overall	7.2 (5.9, 8.4)	10.6 (8.8, 12.5)	0.96 (0.96, 0.97)	0.95 (0.94, 0.95)
One dose - 9 months				
F/M treated severe Shigella diarrhea episodes	0.5 (0.3, 0.7)	0.6 (0.4, 1.0)	0.49 (0.41, 0.62)	0.33 (0.22, 0.49)
F/M treated severe diarrhea episodes of any etiology	0.5 (0.3, 0.7)	0.6 (0.4, 1.0)	0.93 (0.90, 0.96)	0.91 (0.86, 0.95)
F/M treated Shigella diarrhea episodes	3.2 (2.7, 3.8)	4.8 (4, 5.6)	0.61 (0.59, 0.63)	0.42 (0.40, 0.45)
F/M treated diarrhea episodes of any etiology	3.2 (2.7, 3.8)	4.8 (4, 5.6)	0.91 (0.90, 0.92)	0.87 (0.86, 0.89)
F/M courses overall	3.2 (2.7, 3.8)	4.8 (4, 5.6)	0.97 (0.97, 0.97)	0.96 (0.95, 0.96)
F/M exposures to bystander pathogens due to Shigella treatment	6.7 (5.6, 8.0)	9.9 (8.3, 11.7)	0.61 (0.59, 0.64)	0.43 (0.40, 0.46)
F/M exposures to bystander pathogens overall	6.7 (5.6, 8.0)	9.9 (8.3, 11.7)	0.97 (0.96, 0.97)	0.95 (0.94, 0.96)
Two doses - 6 months & 9 months				
F/M treated severe Shigella diarrhea episodes	0.5 (0.3, 0.8)	0.7 (0.4, 1.0)	0.48 (0.4, 0.58)	0.30 (0.21, 0.45)
F/M treated severe diarrhea episodes of any etiology	0.5 (0.3, 0.8)	0.7 (0.4, 1.0)	0.93 (0.89, 0.96)	0.90 (0.86, 0.94)
F/M treated <i>Shigella</i> diarrhea episodes	3.4 (2.8, 3.9)	4.9 (4.2, 5.8)	0.60 (0.58, 0.61)	0.40 (0.38, 0.43)
F/M treated diarrhea episodes of any etiology	3.4 (2.8, 3.9)	4.9 (4.2, 5.8)	0.91 (0.90, 0.92)	0.87 (0.85, 0.88)
F/M courses overall	3.4 (2.8, 3.9)	4.9 (4.2, 5.8)	0.97 (0.96, 0.97)	0.95 (0.95, 0.96)
F/M exposures to bystander pathogens due to Shigella treatment	6.9 (5.8, 8.2)	10.2 (8.6, 12.0)	0.60 (0.58, 0.62)	0.41 (0.39, 0.44)
F/M exposures to bystander pathogens overall	6.9 (5.8, 8.2)	10.2 (8.6, 12.0)	0.97 (0.96, 0.97)	0.95 (0.94, 0.96)
Two doses - 9 months & 12 months				
F/M treated severe Shigella diarrhea episodes	0.5 (0.2, 0.7)	0.6 (0.3, 0.9)	0.52 (0.42, 0.63)	0.35 (0.24, 0.50)
F/M treated severe diarrhea episodes of any etiology	0.5 (0.2, 0.7)	0.6 (0.3, 0.9)	0.93 (0.90, 0.96)	0.91 (0.86, 0.95)
F/M treated <i>Shigella</i> diarrhea episodes	3.1 (2.6, 3.7)	4.5 (3.8, 5.4)	0.63 (0.61, 0.65)	0.45 (0.42, 0.48)
F/M treated diarrhea episodes of any etiology	3.1 (2.6, 3.7)	4.5 (3.8, 5.4)	0.92 (0.91, 0.93)	0.88 (0.86, 0.89)
F/M courses overall	3.1 (2.6, 3.7)	4.5 (3.8, 5.4)	0.97 (0.97, 0.98)	0.96 (0.95, 0.96)
F/M exposures to bystander pathogens due to Shigella treatment	6.3 (5.2, 7.5)	9.3 (7.7, 11.1)	0.64 (0.61, 0.66)	0.47 (0.43, 0.50)
F/M exposures to bystander pathogens overall	6.3 (5.2, 7.5)	9.3 (7.7, 11.1)	0.97 (0.96, 0.97)	0.95 (0.95, 0.96)
Two doses - 12 months & 15 months				

### Table 4. Absolute and relative differences in fluoroquinolone/macrolide (F/M) outcomes in among five vaccine scenarios with 60% and 80% full vaccine efficacies and no indirect or boosting protection.

F/M treated severe Shigella diarrhea episodes	0.4 (0.2, 0.7)	0.5 (0.3, 0.9)	0.57 (0.47, 0.69)	0.42 (0.29, 0.58)
F/M treated severe diarrhea episodes of any etiology	0.4 (0.2, 0.7)	0.5 (0.3, 0.9)	0.94 (0.91, 0.97)	0.92 (0.87, 0.96)
F/M treated Shigella diarrhea episodes	2.6 (2.2, 3.1)	3.9 (3.2, 4.6)	0.68 (0.66, 0.71)	0.53 (0.50, 0.57)
F/M treated diarrhea episodes of any etiology	2.6 (2.2, 3.1)	3.9 (3.2, 4.6)	0.93 (0.92, 0.94)	0.90 (0.88, 0.91)
F/M courses overall	2.6 (2.2, 3.1)	3.9 (3.2, 4.6)	0.98 (0.97, 0.98)	0.96 (0.96, 0.97)
F/M exposures to bystander pathogens due to Shigella treatment	5.3 (4.3, 6.4)	7.8 (6.4, 9.4)	0.70 (0.67, 0.73)	0.55 (0.51, 0.59)
F/M exposures to bystander pathogens overall	5.3 (4.3, 6.4)	7.8 (6.4, 9.4)	0.97 (0.97, 0.98)	0.96 (0.95, 0.97)

**Figure 1.** Percent reductions in diarrhea outcomes among five vaccine scenarios with 60% (A) and 80% (B) full vaccine efficacies and no indirect or boosting protection.

**Figure 2.** Percent reductions in diarrhea outcomes with the addition of indirect and boosting protection among the 9- and 12-month vaccine dosing scenario with 60% full vaccine efficacy.

**Figure 3.** Percent reductions in fluroquinolone and macrolide (F/M) use outcomes among five vaccine scenarios with 60% (A) and 80% (B) full vaccine efficacies and no indirect or boosting protection.

**Figure 4.** Percent reductions in fluroquinolone and macrolide (F/M) use outcomes with the addition of indirect and boosting protection among the 9- and 12-month vaccine dosing scenario with 60% full vaccine efficacy.









Vaccine combination E Direct E Direct + indirect E Direct + boost Direct + indirect + boost